Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Coma, Vegetative State, Minimally Conscious State: Frequent Misdiagnoses And Inconsistent Standards In Europe Pose Ethical Problems
"Latest research raises important ethical issues concerning our care for patients with chronic consciousness disorders," said Professor Gustave Moonen (Liege, Belgium), past president of the European Neurological Society (ENS), at a press conference at the current ENS Congress. This major meeting in European neurology is gathering more than 2,900 experts from all over the world in Milan. "This is all the more important as studies have shown that more than a third of patients given an initial diagnosis of vegetative state or persistent vegetative state show minimal signs of consciousness under more detailed examination."
generic viagra online
Scientists Discover Possible Link Between Missing DNA And Neuroblastoma, A Deadly Childhood Cancer
Discovering for the first time that copy number variation or CNV, where a strip of DNA is duplicated or missing, may
News of the day
Pfizer's Oral JAK-3 Inhibitor Demonstrates Statistically Significant Response For Patients With Rheumatoid Arthritis, New Phase 2 Studies Show
Pfizer announced today that data from two new mid-stage clinical studies of the company"s oral JAK-3 inhibitor, CP-690,550, showed statistically significant response versus placebo for patients with rheumatoid arthritis (RA). Data from these two Phase 2 trials and one ongoing open-label safety study are being presented this week at the 10th Annual Congress of the European League Against Rheumatism (EULAR). These results confirm findings from two previously reported Phase 2 studies in RA and have been used to support dose selection for Phase 3.
Nutrition

Meda: FDA Approval For Onsolis Anticipated During Summer 2009

Since August 2008, Meda (STO:MEDAA) and BioDelivery Sciences International (BDSI) have worked in close collaboration with the U.S. Food and Drug Administration (FDA) to complete the final requirement of a Risk Evaluation and Mitigation Strategy (REMS) program for Onsolis (fentanyl - treatment of breakthrough cancer pain). Last Friday, FDA"s review Division informed Meda and BDSI that they had reached agreement with the REMS for Onsolis, but that the FDA needed some additional time to complete the final senior level sign off. Meda therefore expects Onsolis to be approved by the FDA during summer, which could enable a fourth quarter 2009 launch, as previously anticipated. MEDA AB (publ) is a leading international specialty pharma company. The company specialises in marketing and pharmaceutical development in late clinical stage. Acquisitions and long-term partnerships drive the company"s strategy. Meda is represented by its own organizations in about 40 countries. Meda"s products are sold in 120 countries worldwide. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange Stockholm. Find out more, visit http://www.meda.se. MEDA AB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009